Indian biopharmaceutical company Biocon is set to report its third quarter results on Thursday. Here are key factors to watch out for: It is expected to be a strong quarter for the company. The revenue is likely to grow around 30 percent. Margin expansion of around 400 basis points seen, led by higher margin products. One basis point is a hundredth of a percentage point. Profit is expected to see a growth of 79 percent. Within the biosimilar business, the one thing which is going to drive growth will be the launch of Pegfilgrastim in the US, the cancer biosimilar. Branded formulation segment is likely to follow biologics with strong growth of 20-25 percent.